Phase I NeoVax Personalized Neo-Antigen Vaccine Targeting Patient-Specific Tumor Mutations

This study evaluates the safety and immune response of NeoVax combined with poly ICLC and nivolumab in patients with metastatic or refractory melanoma, breast cancer, and non-small cell lung cancer. Conducted at Fred Hutchinson Cancer Center in Seattle, the trial explores a personalized approach to generate cytolytic T cell responses against patient-specific tumor neo-antigens.